CAR-T Clinical Hold Adds To 2Seventy’s Headwinds

Abecma Revenues Set To Decline In Q3

 
• By Andrew McConaghie

An early stage CAR-T trial in acute myeloid leukemia has been halted after a patient death, adding to 2Seventy’s difficulties in growing sales of its myeloma treatment Abecma.

Cambridge, MA Massachusetts Avenue and Vassar St on campus on MIT campus
2seventy Bio remains in Cambridge, MA, nearly two years after spinning out from Bluebird Bio. • Source: Shutterstock

More from Business

More from Scrip